GlobeNewswire by notified

Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska

Share

Press release
Malmö, Sweden, June 22, 2022  

Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska

Acarix continues its US expansion by partnering with Strategic Health AK, a healthcare provider covering tribal and rural areas of Alaska. Acarix has received initial orders of CADScor®Systems to be used across health regions in Alaska.

Providing health care to remote populations in Alaska is challenging, and cardiac care is no different. Alaskan natives have shown to have higher prevalence of cardiovascular disease and less access to healthcare resources. Strategic Health AK is an Alaska-based healthcare provider offering preventive health services to elevate the health status of Alaska Native communities and manage health needs in family medicine clinics in local communities. A goal is to improve the use of diagnostic point-of-care services to reduce the need for lengthy travel and further clinical assessments.

 “I am passionate about improving overall care delivery, especially in the tribal populations and a technology like the CADScor®System directly meets an already expressed need for rapid assessment of coronary artery disease on location in these communities. Partnering with Acarix will be very exciting and I look forward to the collaborative effort we will make to improve cardiac care in Alaska”, comments Savanah Evans, CEO of Strategic Health AK.

“I was immediately touched when I met Savanah and learned about the challenges faced by the Alaskan tribal communities. Acarix solutions are not just ideal for urban use, but also in remote and rural regions to help quickly assess patients with chest pain and suspected coronary artery disease, while helping to improve cardiac care efficiency at a fraction of the cost. The partnership with Strategic Health AK is very exciting and will enable our solutions to be available to many Alaskans in need”, comments Helen Ljungdahl Round, President and CEO of Acarix.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770 283, email: helen.round@acarix.com

The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire.

About Acarix:
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cool Company Ltd. – Formation Completed1.7.2022 18:46:54 CEST | Press release

Golar LNG Limited ("Golar") announces today that it has sold to Cool Company Ltd. (“CoolCo”) the management organization responsible for the technical and commercial management of LNG carriers, and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel became CoolCo employees. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing Interim CEO Karl Fredrik Staubo. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activitie

Cool Company Ltd. - Formation Completed1.7.2022 18:37:43 CEST | Press release

Cool Company Ltd. ("CoolCo" or the "Company") is pleased to announce today that it has acquired from Golar Management (Bermuda) Limited the management organization responsible for the technical and commercial management of its LNG carriers and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel become employees of CoolCo. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing interim CEO Karl Fredrik Staubo. Richard Tyrrell commented: “CoolCo is delighted to formally welcome the members of the Golar LNG team that provide first class technical and commercial management services to our owned fleet of eight LNG carriers, in addition to providing such services to 20 third party vessels. The acquisi

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic1.7.2022 16:00:10 CEST | Press release

Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after an order from BARDA for the delivery of 500,000 doses of the vaccine in 2022 in response to the current monkeypox outbreak. With a previous order from BARD

Den amerikanske regering bestiller yderligere vacciner mod abekopper fra Bavarian Nordic1.7.2022 16:00:10 CEST | pressemeddelelse

Bavarian Nordic skal levere yderligere 2,5 mio. doser JYNNEOS® vaccineRåvaccine, produceret under tidligere kontrakter med BARDA, vil blive anvendt til færdigproduktion af doserneLeverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i 2023, hvor hovedparten af doserne vil blive leveret KØBENHAVN, Danmark, 1. juli 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har bestilt yderligere 2,5 mio. doser af den flydende-frosne udgave af JYNNEOS®, en ikke-replikerende koppevaccine, og den eneste FDA-godkendte vaccine mod abekopper. Leverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i begyndelsen af 2023. Denne ordre er afgivet få uger efter en anden ordre fra BARDA på levering af 500.000 doser af vaccinen i 2022 til brug i forbindelse med det aktuelle udbrud af abekopper. Med en

Incap Corporation: INCAP GROUP’S HALF-YEAR FINANCIAL REPORT FOR JANUARY–JUNE 2022 AND WEBCAST 28 JULY 20221.7.2022 14:30:00 CEST | Press release

Incap Corporation Press release 1 July 2022 at 3:30 p.m. EEST The corrected release includes the time of the webcast. Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company's website at https://incapcorp.com/reports-and-presentations/. Webcast The company will hold a webcast on Thursday, 28 July 2022 at 2:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap's UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report. During the webcast, the public can ask questions in the chat room at the address mentioned above. The recording of the broadcast will be available on the